IMMP
$0.41
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Intraday
Recent News
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Top 5 Upgrades: HSBC upgraded Nio (NIO) to Buy from Hold with a price target of $6.80, up from $4.80.
Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination
The company will now assess the available data to determine its next steps in progressing efti’s development across multiple solid tumour indications.
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure
Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA.
3 ASX Penny Stocks With Market Caps Under A$600M
Australian shares are on the rise, bolstered by a strong February reporting season and modest gains on Wall Street, contributing to an optimistic outlook for investors. For those willing to explore beyond the well-known blue-chip stocks, penny stocks—often representing smaller or newer companies—offer intriguing possibilities. While the term may seem outdated, these stocks continue to present opportunities for growth at lower price points when supported by solid financials and fundamentals.
Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 50% of the company
Key Insights Significantly high institutional ownership implies Immutep's stock price is sensitive to their trading...